Ramsay Stattman Vela & Price Inc. Acquires 268 Shares of Becton Dickinson and Co (BDX)

Share on StockTwits

Ramsay Stattman Vela & Price Inc. increased its holdings in shares of Becton Dickinson and Co (NYSE:BDX) by 0.6% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 43,044 shares of the medical instruments supplier’s stock after purchasing an additional 268 shares during the period. Becton Dickinson and makes up about 3.9% of Ramsay Stattman Vela & Price Inc.’s holdings, making the stock its 3rd biggest position. Ramsay Stattman Vela & Price Inc.’s holdings in Becton Dickinson and were worth $10,749,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in BDX. Oregon Public Employees Retirement Fund grew its stake in Becton Dickinson and by 22,485.4% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 6,574,612 shares of the medical instruments supplier’s stock worth $29,000 after purchasing an additional 6,545,502 shares during the period. Ronna Sue Cohen lifted its holdings in shares of Becton Dickinson and by 24,129.0% during the first quarter. Ronna Sue Cohen now owns 5,734,031 shares of the medical instruments supplier’s stock valued at $5,734,000 after acquiring an additional 5,710,365 shares during the period. Norges Bank bought a new position in shares of Becton Dickinson and during the fourth quarter valued at $515,703,000. Mackenzie Financial Corp lifted its holdings in shares of Becton Dickinson and by 27.7% during the fourth quarter. Mackenzie Financial Corp now owns 1,943,752 shares of the medical instruments supplier’s stock valued at $437,966,000 after acquiring an additional 421,825 shares during the period. Finally, BlackRock Inc. lifted its holdings in shares of Becton Dickinson and by 1.9% during the fourth quarter. BlackRock Inc. now owns 19,384,283 shares of the medical instruments supplier’s stock valued at $4,367,665,000 after acquiring an additional 355,223 shares during the period. 85.24% of the stock is owned by institutional investors and hedge funds.

Shares of NYSE:BDX opened at $225.93 on Friday. Becton Dickinson and Co has a twelve month low of $208.62 and a twelve month high of $265.87. The firm has a market capitalization of $60.80 billion, a PE ratio of 20.52, a price-to-earnings-growth ratio of 1.69 and a beta of 1.16. The company has a debt-to-equity ratio of 0.82, a current ratio of 0.96 and a quick ratio of 0.59.

Becton Dickinson and (NYSE:BDX) last announced its earnings results on Thursday, May 9th. The medical instruments supplier reported $2.59 earnings per share for the quarter, beating the Zacks’ consensus estimate of $2.57 by $0.02. Becton Dickinson and had a return on equity of 14.58% and a net margin of 5.88%. The company had revenue of $4.20 billion during the quarter, compared to analyst estimates of $4.25 billion. During the same period last year, the company posted $2.65 earnings per share. The firm’s quarterly revenue was down .6% compared to the same quarter last year. Equities analysts anticipate that Becton Dickinson and Co will post 11.7 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 28th. Stockholders of record on Friday, June 7th will be paid a $0.77 dividend. The ex-dividend date of this dividend is Thursday, June 6th. This represents a $3.08 dividend on an annualized basis and a dividend yield of 1.36%. Becton Dickinson and’s dividend payout ratio (DPR) is presently 27.97%.

A number of brokerages have issued reports on BDX. Wells Fargo & Co cut their price objective on Becton Dickinson and from $280.00 to $265.00 and set an “outperform” rating for the company in a report on Monday. Barclays raised Becton Dickinson and from an “equal weight” rating to an “overweight” rating and set a $266.00 price objective for the company in a report on Monday. BMO Capital Markets cut their price objective on Becton Dickinson and from $272.00 to $270.00 and set a “market perform” rating for the company in a report on Friday, May 10th. Morgan Stanley cut their price objective on Becton Dickinson and from $255.00 to $250.00 and set an “equal weight” rating for the company in a report on Friday, May 10th. Finally, UBS Group cut their price objective on Becton Dickinson and from $265.00 to $250.00 and set a “neutral” rating for the company in a report on Friday, May 10th. Six research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $255.31.

In related news, CEO Vincent A. Forlenza sold 8,309 shares of Becton Dickinson and stock in a transaction dated Friday, March 15th. The stock was sold at an average price of $255.13, for a total value of $2,119,875.17. Following the completion of the sale, the chief executive officer now directly owns 222,785 shares in the company, valued at $56,839,137.05. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Vincent A. Forlenza sold 11,340 shares of Becton Dickinson and stock in a transaction dated Monday, February 25th. The stock was sold at an average price of $250.40, for a total value of $2,839,536.00. Following the completion of the sale, the chief executive officer now owns 227,250 shares of the company’s stock, valued at $56,903,400. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 31,384 shares of company stock valued at $7,901,023. 0.12% of the stock is currently owned by corporate insiders.

COPYRIGHT VIOLATION WARNING: “Ramsay Stattman Vela & Price Inc. Acquires 268 Shares of Becton Dickinson and Co (BDX)” was first posted by Week Herald and is the property of of Week Herald. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. & international copyright and trademark laws. The legal version of this news story can be read at https://weekherald.com/2019/05/17/ramsay-stattman-vela-price-inc-acquires-268-shares-of-becton-dickinson-and-co-bdx.html.

Becton Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

See Also: Understanding Relative Strength Index

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.